3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
3
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
35
Recurrence
27
Multiple Myeloma
27
Leukemia, Lymphocytic, Chronic, B-Cell
27
Lymphoma, Non-Hodgkin
25
Lymphoma
20
Neoplasms
16
Lymphoma, Large B-Cell, Diffuse
16
Lymphoma, B-Cell
15
Lymphoma, Follicular
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma, Mantle-Cell
13
Leukemia
13
Carcinoma, Non-Small-Cell Lung
13
Stomach Neoplasms
11
Ovarian Neoplasms
9
Pancreatic Neoplasms
8
Neoplasm Metastasis
8
Triple Negative Breast Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Head and Neck Neoplasms
7
Carcinoma, Renal Cell
7
Uterine Cervical Neoplasms
6
Myelodysplastic Syndromes
6
Melanoma
6
Lymphoma, B-Cell, Marginal Zone
6
Breast Neoplasms
6
Liposarcoma, Myxoid
5
Colorectal Neoplasms
5
Burkitt Lymphoma
5
Interventions
pembrolizumab
7
Ipilimumab
7
Nivolumab
5
Melphalan
5
Dacarbazine
3
tebentafusp
2
sotrastaurin
2
binimetinib
2
Pemetrexed
2
Crizotinib
2
ADI PEG20
2
utomilumab
1
trametinib
1
tocilizumab
1
siremadlin
1
ruxolitinib
1
relatlimab
1
obinutuzumab
1
fludarabine phosphate
1
fludarabine
1
cemiplimab
1
avelumab
1
Watchful Waiting
1
Toll-Like Receptor 1
1
Standard of Care
1
Solutions
1
Rose Bengal
1
Protein Kinase C
1
Polyethylene Glycols
1
Opdualag
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uveal Melanoma
×
fludarabine
×
Clear all
NCT07627698
2026-06-04
DUET-MEL
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled